On Apr. 29, 2020, Windtree Therapeutics announced it has enrolled the first patient into its AEROSURF phase 2b bridging study in premature infants with respiratory distress syndrome.

This bridging study is intended to complete the phase 2 clinical program for AEROSURF and transition clinical development to phase 3 by validating the performance of the new aerosol delivery system in the neonatal intensive care unit and a more intensive dosing regimen.